PharmaSGP Holding SE
PharmaSGP Holding SE manufactures and sells over-the-counter drugs and other healthcare products in Germany. The company's pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage creams for the treatment of various pain conditions; RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil … Read more
PharmaSGP Holding SE (PSG) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2025: 0.115x
Based on the latest financial reports, PharmaSGP Holding SE (PSG) has a cash flow conversion efficiency ratio of 0.115x as of March 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€4.22 Million) by net assets (€36.67 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
PharmaSGP Holding SE - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how PharmaSGP Holding SE's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
PharmaSGP Holding SE Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PharmaSGP Holding SE ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kainos Medicine Inc
KQ:284620
|
-0.400x |
|
Southern Energy Corp
V:SOU
|
0.062x |
|
Iz Hayvancilik Tarim ve Gida Sanayi Ticaret AS
IS:IZINV
|
-0.336x |
|
Generic Sweden publ AB
ST:GENI
|
0.190x |
|
HeraMED Limited
F:1I4
|
-0.309x |
|
Prestige Wealth Inc.
NASDAQ:AURE
|
0.284x |
|
TREJHARA SOLUTIONS LIMITED
NSE:TREJHARA
|
0.010x |
|
Ecocab Co. Ltd
KQ:128540
|
0.092x |
Annual Cash Flow Conversion Efficiency for PharmaSGP Holding SE (2014–2024)
The table below shows the annual cash flow conversion efficiency of PharmaSGP Holding SE from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €31.96 Million | €24.88 Million | 0.778x | +16.15% |
| 2023-12-31 | €39.75 Million | €26.64 Million | 0.670x | -15.68% |
| 2022-12-31 | €31.10 Million | €24.71 Million | 0.795x | +44.12% |
| 2021-12-31 | €22.20 Million | €12.24 Million | 0.551x | -58.95% |
| 2020-12-31 | €11.51 Million | €15.46 Million | 1.343x | +628.25% |
| 2019-12-31 | €95.58 Million | €17.63 Million | 0.184x | -20.63% |
| 2017-12-31 | €61.32 Million | €14.25 Million | 0.232x | +276.99% |
| 2016-12-31 | €57.53 Million | €3.55 Million | 0.062x | -68.67% |
| 2015-12-31 | €53.79 Million | €10.59 Million | 0.197x | +75.71% |
| 2014-12-31 | €48.27 Million | €5.41 Million | 0.112x | -- |